FI/EP 3 199 172 Rajoitetut patenttivaatimukset englannin kielellä

1. Glatiramer acetate for use in treating a human patient suffering from relapsing-remitting multiple sclerosis or who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis, comprising administering to the human patient three subcutaneous injections of 40mg glatiramer acetate for every seven days with at least one day between every subcutaneous injection, wherein the glatiramer acetate is present in a pharmaceutical composition having a pH in the range of 5.5 to 7.0.

2. Glatiramer acetate for use of claim 1, wherein the human patient suffers from relapsing-remitting multiple sclerosis.

3. Glatiramer acetate for use of claim 1, wherein the human patient has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis.

4. Glatiramer acetate for use of any one of claims 1-3 to reduce the cumulative number of enhancing lesions on T_1-weighted images in the human patient.

5. Glatiramer acetate for use of any one of claims 1-4 to reduce the number of new T2 lesions in the brain of the human patient.

6. Glatiramer acetate for use of any one of claims 1-5 to reduce the frequency of relapses in the human patient.

7. Glatiramer acetate for use of any one of claims 1-6 in treating the human patient as effectively as administration of 20mg of glatiramer acetate s.c. daily.

8. Glatiramer acetate for use of any one of claims 1-7 to increase the tolerability of glatiramer acetate treatment in the human patient.

9. Glatiramer acetate for use of any one of claims 1-7 to reduce the frequency of an immediate post injection reaction relative to daily subcutaneous administration of 20 mg glatiramer acetate.

10. Glatiramer acetate for use of claim 9, wherein the immediate post injection reaction comprises palpitations, feeling hot, flushing, hot flushes, tachycardia, dyspnoea, chest discomfort, chest pain, non-cardiac chest, asthenia, back pain, bacterial infection, chills, cyst, face edema, fever, flu syndrome, infection, neck pain, pain, migrane, syncope, tachycardia, vasodilatation, anorexia, diarrhea, gastroenteritis, gastrointestinal disorder, nausea, vomiting, ecchymosis, peripheral edema, arthralgia, agitation, anxiety, confusion, foot drop, hypertonia, nervousness, nystagmus, speech disorder, tremor, vertigo, bronchitis, dyspnea, laryngismus, rhinitis, erythema, herpes simplex, pruritus, rash, sweating, urticaria, ear pain, eye disorder, dysmenorrheal, urinary urgency, or vaginal moniliasis.

11. Glatiramer acetate for use of any one of claims 1-7 to reduce the frequency of an injection site reaction relative to daily subcutaneous administration of 20 mg glatiramer acetate.

12. Glatiramer acetate for use of claim 11, wherein the injection site reaction comprises erythema, hemorrhage, induration, inflammation, mass, pain, pruritus, urticaria, or welt that occurs immediately around the site of injection.